Dybowska Małgorzata, Kazanecka Barbara, Kuca Paweł, Burakowski Janusz, Czajka Cezary, Grzegorczyk Franciszek, Gralec Renata, Tomkowski Witold
Cardio-Pulmonary Intensive Care Department, National Institute of Tuberculosis and Lung Diseases, ul. Płocka 26, 01-138, Warsaw, Poland.
Int J Emerg Med. 2015 Dec;8(1):36. doi: 10.1186/s12245-015-0087-y. Epub 2015 Oct 7.
Purulent pericarditis (PP) continues to result in a very serious prognosis and high mortality. The most serious complication of pericarditis is constriction. Intrapericardial administration of fibrinolytic agents, although controversial, can prevent the development of constrictions. We present the case of a 63-year-old man with purulent inflammation of the right knee who was admitted to the intensive care unit (ICU) via emergency room orthopedic evaluation because of purulent pericarditis. Subxiphoid pericardiotomy was urgently performed, with 1200 ml of thick purulent fluid evacuated. As prevention for pericardial constriction, it was decided to administer fibrinolysis to the patient's pericardial cavity. Administration of streptokinase was complicated by the occurrence of a severe retrosternal pain and intrapericardial bleeding. Due to insufficiency of antibiotic therapy, 17 days after complicated fibrinolytic therapy with streptokinase, it was decided to administer 20 mg of r-tPA directly into the pericardium. In the following days, there remained a high drainage of purulent secretions. Fever up to 38 °C was still observed despite the use of antibiotics. Nine days after first administration of r-tPA, it was decided to apply the next dose. Daily drainage decreased from 50 to 20 ml in successive days. No fluid accumulation and symptoms and signs of constrictions were observed in clinical examinations as well as in echocardiography performed during 7 years follow-up after discharge.
化脓性心包炎(PP)仍然导致非常严重的预后和高死亡率。心包炎最严重的并发症是缩窄。心包内注射纤溶药物尽管存在争议,但可预防缩窄的发生。我们报告一例63岁男性患者,因右膝化脓性炎症,经急诊室骨科评估后因化脓性心包炎入住重症监护病房(ICU)。紧急进行了剑突下心包切开术,抽出1200毫升浓稠的脓性液体。为预防心包缩窄,决定对患者的心包腔进行纤溶治疗。注射链激酶后出现严重的胸骨后疼痛和心包内出血。由于抗生素治疗不足,在链激酶复杂纤溶治疗17天后,决定将20毫克重组组织型纤溶酶原激活剂(r-tPA)直接注入心包。在接下来的几天里,脓性分泌物引流仍然很多。尽管使用了抗生素,仍观察到高达38℃的发热。首次注射r-tPA九天后,决定应用下一剂。连续几天每日引流量从50毫升降至20毫升。出院后7年随访期间的临床检查及超声心动图检查均未发现液体蓄积及缩窄的症状和体征。